OBS Medical

OBS Medical is delighted to announce the appointment of James Otter as Chief Executive Officer (CEO).

After a career in international marketing and management at Zeneca Agrochemicals (formerly ICI and now Syngenta) he has led a range of smaller engineering and bioscience companies. As a main board director of Spectris plc he led their largest subsidiary, specializing in sound and vibration instrumentation in Denmark. Since then he has led a range of bioscience companies, most recently Hallmarq which specialises in veterinary MRI.  He chairs Hygea VCT which specialises in young bioscience companies.  James has an MA in Natural Sciences from Cambridge, an MBA from INSEAD and speaks fluent French.

Richard Moon, chairman of OBS Medical said, “the board is delighted to welcome James to the company, after the recent merger of Oxford BioSignals and t+ Medical his experience and leadership are ideally matched to the very exciting opportunity in front of OBS Medical”.

Joining the company formally at the beginning of March, James Otter said, “I am delighted to be appointed as CEO of OBS Medical.  The healthcare and pharmaceutical sectors represent an exciting environment for a company with such innovative products and services.  Innovation is needed to address the twin demands of cost reduction and improving health outcomes and OBS Medical can clearly do a great deal to help.  It’s a very exciting prospect”.